Cromakalim: Embryonic effects and reduction of tolbutamide-induced dysmorphogenesis in vitro

Teratology

Volumn 60, Issue 5, 1999, Pages 260-264

  Smoak, Ida W ^a,b  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b R ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CROMAKALIM; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGENITAL MALFORMATION; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; HEART RATE; HYPERPOLARIZATION; MOUSE; NEURAL TUBE; NONHUMAN; ORGANOGENESIS; PRIORITY JOURNAL; SMOOTH MUSCLE RELAXATION; SOMITE; YOLK SAC;

EID: 0033504649     PISSN: 00403709     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9926(199911)60:5<260::AID-TERA6>3.0.CO;2-P     Document Type: Article

References (33)

1. Ban Y, Konishi R, Kawana K, Nakatsuka T, Fujii T, Manson JM. 1994. Embryotoxic effects of L-691,121, a class III antiarrhythmic agent, in rats. Arch Toxicol 69: 65-71.
2. Belisle RJ, Long SY. 1976. Tolbutamide treatment of pregnant mice: repeated administration reduces fetal lethality. Teratology 13: 65-70.
3. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
4. Buckingham RE, Clapham JC, Hamilton TC, Longman SD, Norton J, Poyser RH. 1986. BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models. J Cardiovasc Pharmacol 8: 798-804.
5. + channels protect the myocardium against ischemia-reperfusion damage. Circ Res 69: 571-581.
6. Davies MP, An RH, Doevendans P, Kubalak S, Chien KR, Kass RS. 1996. Developmental changes in ionic channel activity in the embryonic murine heart. Circ Res 78:15-25.
7. DeMeyer R. 1961. Etude experimentale de la glycoregulation gravidique et de l'action teratogene des perturbations du metabolisme glucidique. Bruxelles: Arscia.
8. Ferner RE, Antsiferov ML, Kelman AW, Alberti KGMM, Rawlins MD. 1991. The relationships between dose and concentration of tolbutamide and insulin and glucose responses in patients with non-insulin-dependent diabetes. Eur J Clin Pharmacol 40: 163-168.
9. Fox JS, Whitehead E, Shanks RG. 1991. Cardiovascular effects of cromakalim (BRL34915) in healthy volunteers. Br J Clin Pharmacol 32: 45-49.
10. Hamilton TC, Weir SW, Weston AH. 1986. Comparison of the effects of BRL 34915 and verapimil on electrical and mechanical activity in rat portal vein. Br J Pharmacol 88: 103-111.
11. Hamilton TC, Weston AH. 1989, Cromakalim, nicorandil and pinacidil: novel drugs which open potassium channels in smooth muscle. Gen Pharmacol 20: 1-9.
12. Kaku K, Inoue Y, Kaneko T. 1995. Extrapancreatic effects of sulfonylurea drugs. Diabetes Res Clin Pract 28 Suppl.: S105-108.
13. McColl JD, Robinson S, Globus M. 1967. Effect of some therapeutic agents on the rabbit fetus. Toxicol Appl Pharmacol 10: 244-252.
14. McDonald A, MacDonald E, Wadsworth RM, Scott PJW. 1993. Vasodilator action of cromakalim on human mesenteric artery. Eur J Pharmacol 240: 303-305.
15. New DAT. 1978. Whole-embryo culture and the study of mammalian embryos during organogenesis. Biol Rev 53: 81-122.
16. Panten U, Schwanstecher M, Schwanstecher C. 1996. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol 104: 1-9.
17. Quast U, Cook NS.1989. In vitro and in vivo comparison of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide. J Pharmacol ExpTher 250: 261-271.
18. + channel openers, a class of drugs with vasorelaxant and cardioprotective properties. Life Sci 47: 1693-1705.
19. Smithberg M. 1963. Teratogenic effects of tolbutamide on the early development of the fish, Oryzias latipes. Teratology 2: 205-213.
20. Smithberg M, Runner MN. 1963. Teratogenic effects of hypoglycemic treatments in inbred strains of mice. Am J Anat 113: 479-489.
21. Smoak IW. 1992. Teratogenic effects of tolbutamide on early-somite mouse embryos in vitro. Diabet Res Clin Pract 17: 161-167.
22. Smoak IW. 1993. Embryopathic effects of the oral hypoglycemic agent chlorpropamide in cultured mouse embryos. Am J Obstet Gynecol 169: 409-414.
23. Smoak IW. 1994. Embryopathic effects of diazoxide and the reduction of sulfonylurea-induced dysmorphogenesis in vitro. Toxic in Vitro 5: 1121-1127.
24. Smoak IW, Emanuel AN. 1998. Tolbutamide: Placenta transfer, tissue distribution, and metabolic effects in murine embryos. Pharmacol Toxicol 82: 203-208.
25. Spence SG, Vetter C, Hoe CM. 1994. Effects of the class III antiarrhythmic, dofetilide (UK-68,798) on the heart rate of midgestation rat embryos, in vitro. Teratology 49: 282-292.
26. Sturgess NC, Ashford MLJ, Cook DL, Hales CN. 1985. The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet 8453: 474-475.
27. Thomas P, Dixon MS, Winterton SJ, Sheridan DJ. 1990. Acute haemodynamic effects of cromakalim in patients with angina pectoris. Br J Clin Pharmacol 29: 325-331.
28. Tsiani E, Ramlal T, Leiter LA, Klip A, Fantus IG. 1995. Stimulation of glucose uptake and increased plasma membrane content of glucose transporters in L6 skeletal muscle cells by the sulfonylureas gliclazide and glyburide. Endocrinology 136: 2505-2512.
29. Tuchmann-Duplessis H, Mercier-Parot L.1962. Repercussions de quelques hypoglycemiants sur la gestation et le development foetal du rat. J Diabet 10: 141-149.
30. Webster WS, Brown-Woodman PD, Snow MD, Danielsson BR. 1996. Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity. Teratology 53: 168-175.
31. Winquist RJ, Heaney LA, Wallace AA, Baskin EP, Stein RB, Garcia ML, Kaczorowski GJ. 1989. Glyburide blocks the relaxation response to BRL 34915 (cromakalim), minoxidil sulfate and diazoxide in vascular smooth muscle. J Pharmacol Exp Ther 248 149-156.
32. + channel family in rat ventricular myocytes. Am J Physiol 272: H1741-H1750.
33. Ziegler MH, Grafton TF, Hansen DK. 1993. The effect of tolbutamide on rat embryonic development in vitro. Teratology 48: 45-51.